ReviewThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2022
COVID-19 and myocarditis: a review of literature.
Review in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 58 citations in OpenAlex.
- Antiviral innate immunity in myocarditis: mechanisms and emerging therapeutics.Experimental & molecular medicine · 2026Review
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- Immunization induces inflammation in the mouse heart during spaceflight.BMC genomics · 2025Article
- Assessing outcomes of acute myocarditis in Saudi Arabia: A retrospective tertiary center experience.Saudi medical journal · 2025Article
- Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the global burden of disease study 1990-2021.BMC cardiovascular disorders · 2024Article
- Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches.Biomedicines · 2024Review
- Impact of COVID-19 infection on the in-hospital outcome of patients hospitalized for heart failure with comorbid atrial fibrillation: Insight from the National Inpatient Sample (NIS) database 2020.Journal of arrhythmia · 2024Article
- Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice.Nature communications · 2024Article
- Exploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis.International journal of molecular sciences · 2024Article
- Trends in admissions for COVID-19 in the United States between April 2020 and December 2021 and cardiovascular events.Archives of medical sciences. Atherosclerotic diseases · 2024Article
- Fulminant Myocarditis with SARS-CoV-2 Infection: A Narrative Review from the Case Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Clinical outcome of established diagnostic and treatment modalities of COVID-19-associated myocarditis: a systematic review.Annals of medicine and surgery (2012) · 2023Article
- Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature.Cureus · 2023Review
- Article
- Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination.Scientific reports · 2023Article
- COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors.International journal of molecular sciences · 2023Review
- Impact of COVID-19 on Cardiovascular Disease.Viruses · 2023Review
- Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology.Vaccines · 2023Review
- Covid- 19 Vaccine-induced Myocarditis.Journal of community hospital internal medicine perspectives · 2023Article
- Myocarditis in COVID-19: a focus on the pediatric population.American journal of cardiovascular disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis has been discovered to be a significant complication of coronavirus disease 2019 (COVID-19), a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis seems to have distinct inflammatory characteristics, which make it unique to other viral etiologies. The incidence of COVID-19 myocarditis is still not clear as a wide range of figures have been quoted in the literature; however, it seems that the risk of developing myocarditis increases with more severe infection. Furthermore, the administration of the mRNA COVID-19 vaccine has been associated with the development of myocarditis, particularly after the second dose. COVID-19 myocarditis has a wide variety of presentations, ranging from dyspnea and chest pain to acute heart failure and possibly death. It is important to catch any cases of myocarditis, particularly those presenting with fulminant myocarditis which can be characterized by signs of heart failure and arrythmias. Initial work up for suspected myocarditis should include serial troponins and electrocardiograms. If myocardial damage is detected in these tests, further screening should be carried out. Cardiac magnetic resonance imagining and endomyocardial biopsy are the most useful tests for myocarditis. Treatment for COVID-19 myocarditis is still controversial; however, the use of intravenous immunoglobulins and corticosteroids in combination may be effective, particularly in cases of fulminant myocarditis. Overall, the incidence of COVID-19 myocarditis requires further research, while the use of intravenous immunoglobulins and corticosteroids in conjunction requires large randomized controlled trials to determine their efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.